Margaret Brimble

SapVax LLC develops a platform for generating peptide-based, self-adjuvanting cancer vaccines. Its platform is based on a flexible synthetic method for linking tumor antigens with an adjuvant, which enables the generation of vaccines targeting virtually any peptide tumor antigen. The company was founded by Rod Dunbar and Margaret Brimble in 2016 and is headquartered in Cleveland, OH.

SapVax LLC develops a platform for generating peptide-based, self-adjuvanting cancer vaccines. Its platform is based on a flexible synthetic method for linking tumor antigens with an adjuvant, which enables the generation of vaccines targeting virtually any peptide tumor antigen. The company was founded by Rod Dunbar and Margaret Brimble in 2016 and is headquartered in Cleveland, OH.

SapVax LLC develops a platform for generating peptide-based, self-adjuvanting cancer vaccines. Its platform is based on a flexible synthetic method for linking tumor antigens with an adjuvant, which enables the generation of vaccines targeting virtually any peptide tumor antigen. The company was founded by Rod Dunbar and Margaret Brimble in 2016 and is headquartered in Cleveland, OH.

SapVax LLC develops a platform for generating peptide-based, self-adjuvanting cancer vaccines. Its platform is based on a flexible synthetic method for linking tumor antigens with an adjuvant, which enables the generation of vaccines targeting virtually any peptide tumor antigen. The company was founded by Rod Dunbar and Margaret Brimble in 2016 and is headquartered in Cleveland, OH.

SapVax LLC develops a platform for generating peptide-based, self-adjuvanting cancer vaccines. Its platform is based on a flexible synthetic method for linking tumor antigens with an adjuvant, which enables the generation of vaccines targeting virtually any peptide tumor antigen. The company was founded by Rod Dunbar and Margaret Brimble in 2016 and is headquartered in Cleveland, OH.